Few drugs in modern medicine have as wide a gap between belief and clinical evidence as human growth hormone (hGH). In gyms, wellness clinics, and increasingly in orthopedic and “longevity” practices, hGH is pitched as a tissue-repair drug, an anti-aging drug, a fat-burning drug, and a performance enhancer. So too are the so-called GH secretagogues, such as tesamorelin, ibutamoren, and ipamorelin, which are often used to stimulate endogenous GH release.
The appeal is understandable. Growth hormone sounds like exactly what you would want after an injury, surgery, or a period of forced inactivity. If a tendon is torn, perhaps GH can accelerate collagen repair. If a knee replacement leaves someone inactive for weeks, perhaps GH can blunt muscle loss. And if GH levels decline with age, perhaps replacing some of that lost signal could restore something meaningful that conventional outcomes fail to capture.
These are three different questions, and they need to be separated. First: Does hGH accelerate repair of damaged tissue, such as tendon, ligament, muscle, bone, cartilage, or skin? Second: Does hGH reduce lean-mass loss during immobilization, surgery, or catabolic stress? Third: Does age-related GH decline imply that hGH replacement has some broader rejuvenative benefit in otherwise non-deficient adults?
The answers are not the same. The tissue-repair case is weak. The anti-catabolic case is more plausible, but narrow. The anti-aging case remains mostly a biological extrapolation in search of convincing human outcomes.
The mechanistic story behind these claims is seductive. Growth hormone receptors are present in numerous musculoskeletal (MSK) tissues, and GH reliably raises insulin-like growth factor 1 (IGF-1), one of the most potent anabolic signals in mammalian biology. In preclinical models, IGF-1 stimulates satellite cell proliferation, activates the pro-growth PI3K/AKT/mTOR axis, and drives collagen synthesis in cultured tenocytes and osteoblasts.
The reasoning seems straightforward: If you could raise GH and IGF-1 on demand in an injured person, tendons should heal faster, fractures should knit sooner, and muscles should recover or grow more aggressively.
But this is where the story starts to break down. Systemic GH does not simply deliver a precise repair signal to the injured tissue. It raises circulating IGF-1 largely through hepatic production, mobilizes fatty acids, induces some degree of insulin resistance, causes fluid retention, and changes connective-tissue turnover throughout the body. This is a blunt intervention applied to a process that is local, mechanically regulated, and tissue-specific.
The mechanism is real. The clinical extrapolation is where the story breaks.
We will walk through that evidence. The goal is not to dismiss GH biology. GH is essential, and its deficiency produces real disease. Replacement therapy in documented GH-deficient patients is legitimate medicine, and GH has a defensible role in select catabolic conditions.
The goal is to draw a hard line between those narrow indications and the much grander claim being sold to healthy or near-healthy adults: that hGH can reliably accelerate tissue repair, preserve function after routine orthopedic surgery, enhance performance, or reverse some meaningful component of aging.
These are not equivalent claims. Treating a deficient child, a severely burned patient, or HIV-associated wasting is one category of medicine. Giving hGH to a non-deficient adult after orthopedic injury or as an “anti-aging” intervention is another.
Once we limit ourselves to actual human outcomes in non-deficient adults, the evidence base becomes strikingly thin. There are signals worth discussing, but they are small, inconsistent, and rarely tied to outcomes patients actually feel: less pain, better function, faster return to activity, greater strength, or more complete healing.
